Familial Hypercholesterolemia

Long-term adherence to PCSK9 inhibition was high among a high-risk cohort with familial hypercholesterolemia, which improved LDL goal attainment when added on top of background statin therapy and ezetimibe, researchers reported.

Lipoprotein(a) levels of 67 mg/dL or more may be indicative of similar risk for premature MI as LDL of 180 mg/dL or more in patients with familial hypercholesterolemia, researchers reported.

Among younger patients with ACS, approximately one in 11 had familial hypercholesterolemia, researchers reported in The American Journal of Cardiology.

In a cohort of patients with familial hypercholesterolemia, women were less likely than men to receive high-intensity treatment and reach LDL goals, according to data presented at the National Lipid Association Scientific Sessions.

People with familial hypercholesterolemia and those on long-term, high-intensity statins had no greater risk for dementia than matched controls, per a study published in JAMA Network Open.

In patients with heterozygous familial hypercholesterolemia already taking maximally tolerated lipid-lowering medication, resmetirom lowered LDL, triglycerides, apolipoprotein B and lipoprotein(a) levels vs. placebo, researchers reported.

Homozygous familial hypercholesterolemia, although rare, is frequently undertreated, especially in non-high-income countries, and is sometimes diagnosed after atherosclerosis or aortic stenosis is already present, researchers reported.